Sirtuin 7 super-enhancer drives epigenomic reprogramming in hepatocarcinogenesis
Feng Wu(Wuhan Union Hospital), Ka‐Fai To(Chinese University of Hong Kong), Qin Cao(Chinese University of Hong Kong), Stephen L. Chan(Chinese University of Hong Kong), Joseph J.�Y. Sung(Nanyang Technological University), Yalin Tu(Chinese University of Hong Kong), Alfred S.L. Cheng(Chinese University of Hong Kong), Lemuel L. M. Szeto(Chinese University of Hong Kong), Myth T.S. Mok(Chinese University of Hong Kong), Kevin Y. Yip(Chinese University of Hong Kong), Wei Kang(Chinese University of Hong Kong), Weiqin Yang(Chinese University of Hong Kong), Liangliang Xu(Chinese University of Hong Kong), Patrick Tan(SingHealth), Otto KW. Cheung(Chinese University of Hong Kong), Paul B.S. Lai(Chinese University of Hong Kong)
Cited by 41
Related Papers
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
|Nature Genetics|2015|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k